Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay

Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay

KRAS is one of the most heavily mutated oncogenes in cancer and targeting mutant KRAS with drugs has proven difficult. However, recent FDA approval of the KRAS G12C selective inhibitor sotorasib (AMG-510), has breathed new life into the drive to develop mutant KRAS inhibitors. In an effort to study...

Full description

Bibliographic Details
Main Authors: Matthew Swiatnicki, Laurie Engel, Riva Shrestha, Juliano Alves, Said A. Goueli, Hicham Zegzouti
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:SLAS Discovery
Subjects:
KRAS mutants
Bioluminescence
Immunoassay
MAPK signaling
Phospho ERK
Online Access:http://www.sciencedirect.com/science/article/pii/S2472555222125177

Internet

http://www.sciencedirect.com/science/article/pii/S2472555222125177

Similar Items